Professor Michael Millward

Honorary Associate
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone +61 8 9346 2098
Fax +61 8 9346 2816

Map

Selected grants

2014

  • NITRO Trial: A randomised phase III trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer; Davidson A, Boyer M, Millward M, Mitchell P, McLachlan S, Hughes B; National Health and Medical Research Council (NHMRC)/Project Grants.

2011

  • NITRO: A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer; Davidson A, Millward M, Boyer M, Millward M, Fong K, McLachlan S, Singhal N, Stockler M; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2010

  • Australasian Lung cancer Trials Group (ALTG); Millward M; Cancer Australia/Support for Cancer Clinical Trials - Existing National Cooperative Oncology groups.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 81(3), 422-427. [More Information]
  • Kim, K., Kefford, R., Pavlick, A., Infante, J., Ribas, A., Sosman, J., Fecher, L., Millward, M., McArthur, G., Hwu, P., Long, G., et al (2013). Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology, 31(4), 482-489. [More Information]
  • Nathanson, K., Martin, A., Wubbenhorst, B., Greshock, J., Letrero, R., D'Andrea, K., O'Day, S., Infante, J., Falchook, G., Arkenau, H., Kefford, R., Long, G., et al (2013). Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research, 19(17), 4868-4878. [More Information]
  • Boyer, M., Horwood, K., Pavlakis, N., de Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012). Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pacific Journal of Clinical Oncology, 8(3), 248-254. [More Information]
  • Soo, R., Wang, L., Tham, L., Yong, W., Boyer, M., Lee, H., Lim, H., Millward, M., Liang, S., Beale, P., et al (2006). A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Annals of Oncology, 17(7), 1128-1133.
  • Kefford, R., Beith, J., Van Hazel, G., Millward, M., Trotter, J., Wyld, D., Kusic, R., Shreeniwas, R., Morganti, A., Ballmer, A., et al (2006). A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Investigational New Drugs, 25(3), 247-252. [More Information]
  • Bedikian, A., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., Pavlick, A., DeConti, R., Hersh, E., Hersey, P., et al (2006). Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group. Journal of Clinical Oncology, 24(29), 4738-4745. [More Information]
  • Francken, A., Fulham, M., Millward, M., Thompson, J. (2006). Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. European Journal of Surgical Oncology, 32(7), 780-784. [More Information]
  • Kohonen-Corish, M., Cooper, W., Saab, J., Thompson, J., Trent, R., Millward, M. (2006). Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. The Journal of Investigative Dermatology, 126(1), 167-171. [More Information]
  • Francken, A., Hong, A., Fulham, M., Millward, M., McCarthy, W., Thompson, J. (2005). Detection of unsuspected spinal cord compression in melanoma patients by 18F-fluorodeoxyglucose-positron emission tomography. European Journal of Surgical Oncology, 31(2), 197-204. [More Information]
  • Sharma, R., Boyer, M., Clarke, S., Millward, M. (2005). Gefitinib in advanced non-small cell lung cancer. Internal Medicine Journal, 35(2), 77. [More Information]
  • Millward, M., Joshua, A., Kefford, R., Aamdal, S., Thomson, D., Hersey, P., Toner, G., Lynch, K. (2005). Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. Investigational New Drugs, 23(3), 253-256. [More Information]
  • Chan, A., Hsu, M., Goh, B., Hui, E., Liu, T., Millward, M., Hong, R., Whang-Peng, J., Ma, B., To, K., et al (2005). Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Journal of Clinical Oncology, 23(15), 3568-3576. [More Information]
  • Millward, M., Boyer, M., Lehnert, M., Clarke, S., Rischin, D., Goh, B., Wong, J., McNeil, E., Bishop, J. (2003). Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Annals of Oncology, 14(3), 449-454.
  • Rischin, D., Ackland, S., Smith, J., Garg, M., Clarke, S., Millward, M., Toner, G., Zalcberg, J. (2002). Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodies. Annals of Oncology, 13(11), 1810-1818.
  • Clarke, S., Abratt, R., Goedhals, L., Boyer, M., Millward, M., Ackland, S. (2002). Phase II trial of pemetrexed disodium (ALIMTA[R], LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Annals of Oncology, 13(5), 737-741.
  • Rischin, D., Boyer, M., Smith, J., Millward, M., Michael, M., Bishop, J., Zalcberg, J., Davison, J., Emmett, E., McClure, B. (2000). A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Annals of Oncology, 11, 421-426.
  • Rischin, D., Smith, J., Millward, M., Lewis, C., Richardson, G., Boyer, M., Toner, G., Gurney, H., McKendrick, J. (2000). A phase II trial of paclitaxel and epirubicin in advanced breast cancer. British Journal of Cancer, 83(4), 438-442.
  • Rivory, L., Charles (nee Slaviero), K., Seale, J., Hoskins, J., Boyer, M., Beale, P., Millward, M., Bishop, J., Clarke, S. (2000). Optimizing the erythromycin breath test for use in cancer patients. Clinical Cancer Research, 6, 3480-3485.

Conferences

  • Kirkwood, J., Kefford, R., Logan, T., Mainwaring, P., Millward, M., Pavlick, A., Dar, M., Kathman, S., Laubscher, K., Bell, W. (2006). Phase II trial of iboctadekin (rhIL-18) on a daily X 5 schedule in metastatic melanoma (MM). 2006 American Society of Clinical Oncology (ASCO) Annual Meeting, United States: American Society of Clinical Oncology.

2013

  • Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 81(3), 422-427. [More Information]
  • Kim, K., Kefford, R., Pavlick, A., Infante, J., Ribas, A., Sosman, J., Fecher, L., Millward, M., McArthur, G., Hwu, P., Long, G., et al (2013). Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology, 31(4), 482-489. [More Information]
  • Nathanson, K., Martin, A., Wubbenhorst, B., Greshock, J., Letrero, R., D'Andrea, K., O'Day, S., Infante, J., Falchook, G., Arkenau, H., Kefford, R., Long, G., et al (2013). Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research, 19(17), 4868-4878. [More Information]

2012

  • Boyer, M., Horwood, K., Pavlakis, N., de Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012). Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pacific Journal of Clinical Oncology, 8(3), 248-254. [More Information]

2006

  • Soo, R., Wang, L., Tham, L., Yong, W., Boyer, M., Lee, H., Lim, H., Millward, M., Liang, S., Beale, P., et al (2006). A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Annals of Oncology, 17(7), 1128-1133.
  • Kefford, R., Beith, J., Van Hazel, G., Millward, M., Trotter, J., Wyld, D., Kusic, R., Shreeniwas, R., Morganti, A., Ballmer, A., et al (2006). A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Investigational New Drugs, 25(3), 247-252. [More Information]
  • Bedikian, A., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., Pavlick, A., DeConti, R., Hersh, E., Hersey, P., et al (2006). Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group. Journal of Clinical Oncology, 24(29), 4738-4745. [More Information]
  • Francken, A., Fulham, M., Millward, M., Thompson, J. (2006). Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. European Journal of Surgical Oncology, 32(7), 780-784. [More Information]
  • Kirkwood, J., Kefford, R., Logan, T., Mainwaring, P., Millward, M., Pavlick, A., Dar, M., Kathman, S., Laubscher, K., Bell, W. (2006). Phase II trial of iboctadekin (rhIL-18) on a daily X 5 schedule in metastatic melanoma (MM). 2006 American Society of Clinical Oncology (ASCO) Annual Meeting, United States: American Society of Clinical Oncology.
  • Kohonen-Corish, M., Cooper, W., Saab, J., Thompson, J., Trent, R., Millward, M. (2006). Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. The Journal of Investigative Dermatology, 126(1), 167-171. [More Information]

2005

  • Francken, A., Hong, A., Fulham, M., Millward, M., McCarthy, W., Thompson, J. (2005). Detection of unsuspected spinal cord compression in melanoma patients by 18F-fluorodeoxyglucose-positron emission tomography. European Journal of Surgical Oncology, 31(2), 197-204. [More Information]
  • Sharma, R., Boyer, M., Clarke, S., Millward, M. (2005). Gefitinib in advanced non-small cell lung cancer. Internal Medicine Journal, 35(2), 77. [More Information]
  • Millward, M., Joshua, A., Kefford, R., Aamdal, S., Thomson, D., Hersey, P., Toner, G., Lynch, K. (2005). Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. Investigational New Drugs, 23(3), 253-256. [More Information]
  • Chan, A., Hsu, M., Goh, B., Hui, E., Liu, T., Millward, M., Hong, R., Whang-Peng, J., Ma, B., To, K., et al (2005). Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Journal of Clinical Oncology, 23(15), 3568-3576. [More Information]

2003

  • Millward, M., Boyer, M., Lehnert, M., Clarke, S., Rischin, D., Goh, B., Wong, J., McNeil, E., Bishop, J. (2003). Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Annals of Oncology, 14(3), 449-454.

2002

  • Rischin, D., Ackland, S., Smith, J., Garg, M., Clarke, S., Millward, M., Toner, G., Zalcberg, J. (2002). Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodies. Annals of Oncology, 13(11), 1810-1818.
  • Clarke, S., Abratt, R., Goedhals, L., Boyer, M., Millward, M., Ackland, S. (2002). Phase II trial of pemetrexed disodium (ALIMTA[R], LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Annals of Oncology, 13(5), 737-741.

2000

  • Rischin, D., Boyer, M., Smith, J., Millward, M., Michael, M., Bishop, J., Zalcberg, J., Davison, J., Emmett, E., McClure, B. (2000). A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Annals of Oncology, 11, 421-426.
  • Rischin, D., Smith, J., Millward, M., Lewis, C., Richardson, G., Boyer, M., Toner, G., Gurney, H., McKendrick, J. (2000). A phase II trial of paclitaxel and epirubicin in advanced breast cancer. British Journal of Cancer, 83(4), 438-442.
  • Rivory, L., Charles (nee Slaviero), K., Seale, J., Hoskins, J., Boyer, M., Beale, P., Millward, M., Bishop, J., Clarke, S. (2000). Optimizing the erythromycin breath test for use in cancer patients. Clinical Cancer Research, 6, 3480-3485.

To update your profile click here. For support on your academic profile contact .